We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDRH’s 3-Year Strategic Priorities Will Bring New Focus on Diversity in Trials, Says Regulatory Attorney
CDRH’s 3-Year Strategic Priorities Will Bring New Focus on Diversity in Trials, Says Regulatory Attorney
The FDA’s Center for Devices and Radiological Health (CDRH) announced strategic priorities for 2022 to 2025 earlier this year that will mean some challenges as well as potential benefits for devicemakers, including increased attention to diversity in clinical trials, according to one prominent regulatory attorney.